Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2015; 7(8): 102-110
Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.102
Neoadjuvant or adjuvant therapy for gastric cancer
Laurent Quéro, Sophie Guillerm, Christophe Hennequin
Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France
Author contributions: Quéro L designed, researched and analyzed the literature, and helped write the paper; Guillerm S and Hennequin C analyzed the literature, and helped write the paper.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Laurent Quéro, MD, PhD, Department of Radiation Oncology, Saint Louis Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France. laurent.quero@sls.aphp.fr
Telephone: +33-142-499034 Fax: +33-142-494081
Received: March 10, 2015
Peer-review started: March 13, 2015
First decision: April 13, 2015
Revised: May 8, 2015
Accepted: July 11, 2015
Article in press: July 14, 2015
Published online: August 15, 2015
Processing time: 156 Days and 22.4 Hours
Core Tip

Core tip: Gastric cancer (GC) treatment is controversy, particularly between Asia and Western countries. In this paper, we have performed a systematic and up-to-date review of resectable GC treatment strategies and discussed different treatment options. We have also discribed ongoing clinical randomized phase 3 trials and future directions in GC treatment.